eIF4E is the cap-binding factor and its overexpression in solid tumor cells is associated with higher rates of cancer recurrence and cancer-related death.[4, 5] Various studies have demonstrated the overexpression of eIF4E in solid malignancies including esophageal cancer [6] and breast cancer;[7] however, there are currently no available FDA-approved anti-cancer agents that directly target eIF4E. The gene discussed is EIF4E; the disease is breast cancer.